Study finds varenicline can help young adults quit vaping
Abstract
Varenicline, a smoking cessation drug, can also help young adults quit vaping, according to a study by researchers from Mass General Brigham. The study, Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial, published in JAMA last week, showed that teenagers and young adults who took a varenicline pill twice a day were more than three times as likely to quit vaping as those who received only a text service. For the study, published in the Journal of the American Medical Association last week, researchers recruited 261 participants aged 16‐to‐25 into a randomized clinical trial. There were three groups.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 261 participants or records.
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.